PathAI, a Boston, MA-based provider of artificial intelligence-powered technology for advancing pathology research, secured strategic investments from the Merck Global Health Innovation Fund (Merck GHIF) and Bristol-Myers Squibb.
The company will use the funding to accelerate its clinical development capabilities.
Led by co-founder and Chief Executive Officer Andy Beck M.D., Ph.D., PathAI is a provider of AI-powered research tools and services to improve the accuracy of diagnosis and the efficacy of treatment of diseases like cancer. The company works with life sciences companies and researchers.
These new investments complete PathAI’s $75M Series B investment round. They follow the first tranche of series B, announced in April, and a strategic funding from LabCorp, a global life sciences company that provides comprehensive clinical laboratory and end-to-end drug development service, announced in July.
This latest addition brings total investment in PathAI to over $90M since its founding in 2016.